Literature DB >> 15818731

Inhibitory effect of human telomerase antisense oligodeoxyribonucleotides on the growth of gastric cancer cell lines in variant tumor pathological subtype.

Jing Ye1, Yun-Lin Wu, Shu Zhang, Zi Chen, Li-Xia Guo, Ruo-Yu Zhou, Hong Xie.   

Abstract

AIM: To investigate the inhibitory effect of specialized human telomerase antisense oligodeoxyribonucleotides on the growth of well (MKN-28), moderately (SGC-7901) and poorly (MKN-45) differentiated gastric cancer cell lines under specific conditions and its inhibition mechanism, and to observe the correlation between the growth inhibition ratio and the tumor pathologic subtype of gastric cancer cells.
METHODS: Telomerase activity in three gastric cancer cell lines of variant tumor pathologic subtype was determined by modified TRAP assay before and after the specialized human telomerase antisense oligodeoxyribonucleotides were dealt with under specific conditions. Effect of antisense oligomer under specific conditions of the growth and viability of gastric cancer cell lines was explored by using trypan blue dye exclusion assay, and cell apoptosis was detected by cell morphology observation, flow cytometry and TUNEL assay.
RESULTS: Telomerase activity was detected in well, moderately and poorly differentiated gastric cancer cell lines (the quantification expression of telomerase activity was 43.7TPG, 56.5TPG, 76.7TPG, respectively). Telomerase activity was controlled to 30.2TPG, 36.3TPG and 35.2TPG for MKN-28, SGC-7901 and MKN-45 cell lines respectively after treatment with human telomerase antisense oligomers at the concentration of 5 mumol/L, and was entirely inhibited at 10 mumol/L, against the template region of telomerase RNA component, whereas no inhibition effect was detected in missense oligomers (P<0.05). After treatment with antisense oligomers at different concentrations under specific conditions for 96 h, significant growth inhibition effects were found in MKN-45 and SGC-7901 gastric cancer cell lines (the inhibition ratio was 40.89% and 71.28%), but not in MKN-28 cell lines (15.86%). The ratio of inactive SGC-7901 cells increased according to the prolongation of treatment from 48 to 96 h. Missense oligomers could not lead to the same effect (P<0.05). Apoptosis of SGC-7901 and MKN-45 cells was detected not only by morphology and TUNEL assay but also by flow cytometry. The apoptotic rate reached 33.56% for SGC-7901 cells and 44.75% for MKN-45 cells.
CONCLUSION: The viability and proliferation of gastric cancer cells can be inhibited by antisense telomerase oligomers. The growth inhibition of gastric cancer cells is correlated with concentration, time and sequence specialty of antisense oligomers. The inhibition mechanism of antisense human telomerase oligomers depends not only on the sequence specialty but also on the biological characteristics of gastric cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15818731      PMCID: PMC4305804          DOI: 10.3748/wjg.v11.i15.2230

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Using a non-radioisotopic, quantitative TRAP-based method detecting telomerase activities in human hepatoma cells.

Authors:  R G Zhang; X W Wang; J H Yuan; L X Guo; H Xie
Journal:  Cell Res       Date:  2000-03       Impact factor: 25.617

2.  Antisense effects of DNA-peptide conjugates.

Authors:  Takanori Kubo; Rumiana Bakalova; Hideki Ohba; Masayuki Fujii
Journal:  Nucleic Acids Res Suppl       Date:  2003

Review 3.  Telomerase inhibition and telomere erosion: a two-pronged strategy in cancer therapy.

Authors:  Fred O Odago; Stanton L Gerson
Journal:  Trends Pharmacol Sci       Date:  2003-07       Impact factor: 14.819

Review 4.  Antisense therapy for cancer--the time of truth.

Authors:  Burkhard Jansen; Uwe Zangemeister-Wittke
Journal:  Lancet Oncol       Date:  2002-11       Impact factor: 41.316

5.  Telomere and telomerase in the initial stage of immortalization of esophageal epithelial cell.

Authors:  Zhong-Ying Shen; Li-Yan Xu; En-Min Li; Wei-Jia Cai; Min-Hua Chen; Jian Shen; Yi Zeng
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

6.  Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines.

Authors:  K Naka; H Yokozaki; W Yasui; H Tahara; E Tahara; E Tahara
Journal:  Biochem Biophys Res Commun       Date:  1999-02-24       Impact factor: 3.575

7.  Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma.

Authors:  Eunice S Wang; Kaida Wu; Allison C Chin; Selina Chen-Kiang; Krisztina Pongracz; Sergei Gryaznov; Malcolm A S Moore
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

Review 8.  Telomere inhibition and telomere disruption as processes for drug targeting.

Authors:  Evonne M Rezler; David J Bearss; Laurence H Hurley
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

9.  Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation.

Authors:  S Kondo; Y Tanaka; Y Kondo; M Hitomi; G H Barnett; Y Ishizaka; J Liu; T Haqqi; A Nishiyama; B Villeponteau; J K Cowell; B P Barna
Journal:  FASEB J       Date:  1998-07       Impact factor: 5.191

10.  2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells.

Authors:  Noriyuki Yatabe; Satoru Kyo; Seiji Kondo; Taro Kanaya; Zhuo Wang; Yoshiko Maida; Masahiro Takakura; Mitsuhiro Nakamura; Masaaki Tanaka; Masaki Inoue
Journal:  Cancer Gene Ther       Date:  2002-07       Impact factor: 5.987

View more
  3 in total

1.  Inhibitory effects of antisense phosphorothioate oligodeoxynucleotides on pancreatic cancer cell Bxpc-3 telomerase activity and cell growth in vitro.

Authors:  Yun-Feng Wang; Ke-Jian Guo; Bei-Ting Huang; Yong Liu; Xiao-Yun Tang; Jian-Jun Zhang; Qiang Xia
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

Review 2.  Telomerase inhibition in cancer therapeutics: molecular-based approaches.

Authors:  A P Cunningham; W K Love; R W Zhang; L G Andrews; T O Tollefsbol
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 3.  Gene therapy for gastric cancer: is it promising?

Authors:  Andreas P Sutter; Henry Fechner
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.